4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (October 2021)
39 slides from 4dmedical's shareholder meeting presentation, Oct 28, 2021
Slide 1: Important Notice & Disclaimer
ag Important Notice & Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831, "Company" or "4DMedical”"). This presentation contains summary information about the Company and its subsidiaries ("Group"), and the entities, businesses and assets they own and operate. Infor
Slide 2: 2021 Annual General Meeting
3¢ 4DMedical’ 2021 Annual General Meeting 28 October 2021 4DMedical Limited ACN 161684 831 ASX:4DX
Slide 3: 2021 AGM Agenda
4 2021 AGM Agenda Opening & introductions 1. Procedural matters 2. Chairman's address 3. Managing Director & CEO’s presentation 4. Formal business Closing remarks
Slide 4: 4DMedical Board of Directors & Company Secretary
ag 4DMedical Board of Directors & Company Secretary ‘ Bruce Rathie Non-Executive Director and Chairman (independent) Lusia Guthrie Non-Executive Director (independent) Andreas Fouras PhD. Group Managing Director & Chief Executive Officer dh Julian Sutton Non-Executive Director 2 Dr Robert A. Figlin
Slide 5: Procedural matters
ADMedical 2021 AGM presentation Procedural matters Charlene Stahr, Company Secretary
Slide 6: Procedural matters — how to vote
ag Procedural matters — how to vote 1 2 3 4 Click “Get a Voting Enter your Shareholder Fill out your voting card Click “Submit Vote” or Card’ located at the top Number and click for each item of business “Submit Partial Vote” or bottom of the online “Submit Details and platform Vote”
Slide 7: Procedural matters — how to ask a question (online)
ag Procedural matters — how to ask a question (online) Click “Ask a Question” located at the top or bottom of the online platform Select the item of business from the drop-down menu and type your question into the space provided 3 Once you have typed your question, click “Submit Question”
Slide 8: Procedural matters — how to ask a question (phone)
ag Procedural matters — how to ask a question (phone) Join the Meeting via your landline or mobile phone. From Australia: 1800 577 505 From overseas: +612 9189 2002 When the Chairman calls for questions on each resolution, raise your hand by: pressing *1 (asterisk 1) You can lower your hand at any t
Slide 9: Chairman's address
4DMedical 2021 AGM presentation Chairman's address Bruce Rathie, Non-executive director & Chairman
Slide 10: FY21 financial summary
ag FY21 financial summary Cash reserves 4 860% Operating costs 452% vs PY vs PY $80.88m $24.46m Total income AT1% Loss after taxes Vv 3% vs vs PY $5.77m * $21.42m Sales revenue Vv 82% Our people 4 132% $0.22m _ Other income “159% $5.55m _ 95 staff vs PY * Significant cash reserve, with nil debt, fol
Slide 11: Managing Director & CEO presentation
4DMedical 2021 / Managing Director & CEO presentation Dr Andreas Fouras, Group Managing Director & CEO
Slide 12: Source: Frost & Sullivan 2020 (per annum)
• • • • Source: Frost & Sullivan 2020 (per annum)
Slide 13: Approval for inclusion in the Australian Register of Therapeutic Goods (ARTG)
*Approval for inclusion in the Australian Register of Therapeutic Goods (ARTG)
Slide 14: Commercialisation strategy
Commercialisation strategy Clinical trials (approx. 6+ months) Commercial pilots (approx. 3 weeks - 3 months) ——X—X—__:):2720 _ Research partners delivering the body ee Physicians gaining familiarity with XV of scientific evidence for clinical use as Technology™ and insights for patient care v v v w
Slide 15: Abbreviations
Abbreviations: OHSU: Oregon Health & Science University, COPD: Chronic Obstructive Pulmonary Disease, VQ: Ventilation Perfusion, XV LVAS: X-ray Velocimetry Lung Ventilation Analysis Software. As at 30 June 2021.
Slide 16: Commercial pilot pipeline (AUS & USA)
ag Commercial pilot pipeline (AUS & USA) 4DMedical has rapidly established a strong commercial pilot pipeline comprising of capital city hospitals, national imaging centres and major GP practitioners Pilot stages Pilot in development @ Hospital Network @ Veterans Affairs (VA) Hospital Network (2) Pr
Slide 17: Clinical case study (1)
ag Clinical case study (1) Patient details Male . 45 years old . Clinical history Biopsy-proven silicosis Ex-smoker Right-sided chest discomfort with breathing XV LVAS™ scan Results Tidal volume Ventilation heterogeneity (%) 63.2 total Ventilation defect percentage (%) Summary * Patient history of s
Slide 18: Clinical case study (2)
ag Clinical case study (2) Patient details Clinical history Summary Female + Past history of COVID 19 69 years old + Gastric Oesophageal Reflux * Patient history of COVID-19 infection and Disease recurrent chest infections *_Recurrent chest infections * Patient completed a CT and XV LVAS™ scan that
Slide 19: Staff hires by department
Staff hires by department oO Go-to-Market oO Information Technology Engineering n Imaging Systems / XVD Specialist Team +12 re} Operations re) Clinical & Medical Affairs +2 Regulatory & Quality Affairs * Rapid expansion of our team in line with major business objectives, with staff growing 132% by e
Slide 20: Outlook FY22
Outlook FY22 The Company is focused on the following activities: reviewed medical journals and presentations at conferences to drive awareness, education and adoption at key opinion leading hospitals Establishing commercial pilots with healthcare providers, identified by the Go-to-Market team, for d
Slide 21: Product pipeline
ng Product pipeline Each product is designed to expand applicable indications and market opportunity Overview — Quantifies regional lung function at all Evaluates airflow (ventilation) & blood flow The world’s first dedicated lung function locations in the lungs during active breathing (perfusion) i
Slide 22: Notes: XVD Scanner (Gen 1) milestones
Notes: XVD Scanner (Gen 1) milestones; and VQ product line includes CFPA capabilities.
Slide 23: Formal business
4DMedical 2021 AGM presentation Formal business A
Slide 24: Financial Report, Directors' Report & Auditor's Report
Item 1 Financial Report, Directors’ Report & Auditor’s Report To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30
Slide 25: Remuneration Report
Item 2 Remuneration Report To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2021, is adopted.’ Note: the vote on this resolution is advisory only and does not bind the Di
Slide 26: Remuneration Report
Item 2 Remuneration Report To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2021, is adopted.’ Proxy votes 59,962,963 2,610,079 2)185,415 724,757 92.59% 4.03% 3.37%
Slide 27: Re-election of Dr Robert A. Figlin
ag Item 3 Re-election of Dr Robert A. Figlin Joined Board: 9 December 2016 Background: Dr Figlin MD FACP is a Professor of Medicine and Biomedical Sciences and is the Steven Spielberg Family Chair in Hematology-Oncology, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Dep
Slide 28: Re-election of Dr Robert A. Figlin
ag Item 3 Re-election of Dr Robert A. Figlin To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.5, and for all other purposes, Dr Robert A. Figlin, a non-executive director appoi
Slide 29: Non-executive Directors' Fees
ng Item 4 Non-executive Directors’ Fees To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to
Slide 30: Non-executive Directors' Fees
ng Item 4 Non-executive Directors’ Fees To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to
Slide 31: Grant of Options to the Managing Director & CEO
ng Item 5 Grant of Options to the Managing Director & CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 10.14, Chapter 2E of the Corporations Act 2001 (Cth), and for all other purposes, the grant of 701,719 options to Ma
Slide 32: Grant of Options to the Managing Director & CEO
ng Item 5 Grant of Options to the Managing Director & CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 10.14, Chapter 2E of the Corporations Act 2001 (Cth), and for all other purposes, the grant of 701,719 options to Ma
Slide 33: Ratification of prior issue of shares
ag Item 6(a) Ratification of prior issue of shares —- March 2021 placement (LR 7.1) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 74 and for all other purposes, shareholders approve and ratify the issue of 25,806,436 ful
Slide 34: Ratification of prior issue of shares
ag Item 6(a) Ratification of prior issue of shares —- March 2021 placement (LR 7.1) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 74 and for all other purposes, shareholders approve and ratify the issue of 25,806,436 ful
Slide 35: Ratification of prior issue of shares
ag Item 6(b) Ratification of prior issue of shares — April 2021 share purchase plan (LR 7.1) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 74 and for all other purposes, shareholders approve and ratify the issue of 3,870
Slide 36: Ratification of prior issue of shares
ag Item 7(a) Ratification of prior issue of shares — Tax Exempt Employee Share Plan (LR 7.1) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 74 and for all other purposes, shareholders approve and ratify the issue of 52,04
Slide 37: Ratification of prior issue of shares
ag Item 7(a) Ratification of prior issue of shares - Tax Exempt Employee Share Plan (LR 7.1) To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 74 and for all other purposes, shareholders approve and ratify the issue of 52,04
Slide 38: Approval in respect of the Tax Exempt Employee Share Plan
ag Item 7(b) Approval in respect of the Tax Exempt Employee Share Plan To consider, and if thought fit, to pass, the following as an ordinary resolution: ‘That for the purposes of ASX Listing Rule 71 and in accordance with ASX Listing Rule 72 Exception 13 and for all other purposes, the rules of the
Slide 39: Thank you
xg saovese Thank you Contacts >» Corporate >» Investor Relations >» Media Charlene Stahr Simon Hinsley Matthew Wright Company Secretary +61 401 809 653 +61 451 896 420 companysecretary@4dmedical.com shinsley@4dmedical.com matt@nwrcommunications.com.au www.4DMedical.com 4DMedical 2021 AGM presentatio